Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
about
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAARTNon-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityStructural insights on the role of antibodies in HIV-1 vaccine and therapyDelavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexesSusceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesSelection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitorResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor lovirideSelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anStructure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilidePreclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replicationPotent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivativesAnti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsSusceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysesHighly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolatesS-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsPotent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-PolN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisWhich compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical developmentDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsTrends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, MozambiqueCombinatorial approaches to the prevention and treatment of HIV-1 infectionViral population analysis and minority-variant detection using short read next-generation sequencing.Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringHigh-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania.Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infantsCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primerA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineGenotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
P2860
Q21563427-16FB9844-EDD3-44A4-A721-CA1092BE7865Q24628212-3C003E2B-66AF-44F6-A4F9-D676AAAE21D5Q26829461-38DDA1FE-5DAA-43C5-B77B-A40FE5374976Q28343932-9D46424B-7355-417E-A836-B925F4A4D9D5Q28344140-6D11EE80-175D-463F-9CD7-97FD2ADCADBCQ28367590-514ADEAA-5539-4826-9532-A054EFE2C082Q28367722-E88EB143-270F-48F2-851D-636D0CAA74C9Q28368263-59DCEF5B-0561-4BD9-B96F-A43D9F57F8D8Q28368381-AF3DC29A-6014-49BD-9030-3CF66EF5F3B6Q28369167-149B74A3-0901-49A2-B37F-5688697E3C24Q28369293-7537D4CB-1264-43E1-8BAE-FCB1F56A4011Q28378760-3F282067-3E54-4D62-BBD8-3B5821DF44E7Q28378796-CF066F83-BD48-424F-B4D1-31A6089DADD8Q28378825-CFC97F7B-CC9D-495B-8B8A-489A03364016Q28378831-B5C1E98E-65D2-4364-A12B-F3E66D7DE9E5Q28378840-52F66B94-18D8-4917-AF16-9290592725E3Q28378859-1A423BA0-4051-4177-97D4-86578E2E2148Q28379139-40B09C22-9DEA-4DF7-9E40-FF22866E5B4DQ28379196-A6A55019-D1AD-44C3-8F7B-62AF734DB616Q28379523-3E96CA26-6BE2-4DFF-B9BA-5E3CF7E4F8E5Q28379544-C70DDB9D-4E8F-49C4-8E75-14F5A98C091AQ28379552-6C90AA53-3DBA-4754-B249-BF40795039E8Q28469069-19C62ECB-14DC-4469-A5A2-195845B8AB6CQ28471689-9BF031F0-95DB-4BC4-84C5-6F93A2E4BD63Q28478121-9787BB80-6B47-46F8-88BA-0AFD26D14507Q28478130-D2B1023A-71FB-4514-B909-1D071E3EB38EQ28481393-FA0991C2-D4B1-426D-91EB-3EF38E688F5CQ28546341-B6176C75-D3A1-497C-A0EA-26F954B21792Q30400060-BAD4510F-A552-4BFB-A0DF-52563CEB4672Q30426786-CC7F94D4-06A8-4AA9-A6B7-92EF3D7F1176Q30483107-152902E7-519D-423E-9EAF-68DB87D4DE24Q33303221-B59379B2-1935-4381-953E-C71683842B19Q33312946-2622BD1C-EC68-4B93-A7B5-F3197B8163CCQ33396950-BC15275E-E8E8-4DEB-810B-514C362BC9F6Q33535654-FEE8F8F7-5EBB-452B-B1F1-26C3B4474EF0Q33592278-BCE6E543-12E8-4FD9-868A-C74911829424Q33672541-A73B5945-42CA-4A4B-8E5B-979C93F7796DQ33690164-D67536A1-564B-4677-84DF-21EF6DACBAF9Q33782477-0783BEA1-0CFD-48D0-8E3A-58B6DA05BC46Q33784635-39548D9E-7269-4E60-90F8-037F86682D24
P2860
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Nevirapine resistance mutation ...... type 1 selected during therapy
@ast
Nevirapine resistance mutation ...... type 1 selected during therapy
@en
Nevirapine resistance mutation ...... type 1 selected during therapy
@nl
type
label
Nevirapine resistance mutation ...... type 1 selected during therapy
@ast
Nevirapine resistance mutation ...... type 1 selected during therapy
@en
Nevirapine resistance mutation ...... type 1 selected during therapy
@nl
prefLabel
Nevirapine resistance mutation ...... type 1 selected during therapy
@ast
Nevirapine resistance mutation ...... type 1 selected during therapy
@en
Nevirapine resistance mutation ...... type 1 selected during therapy
@nl
P2093
P2860
P1433
P1476
Nevirapine resistance mutation ...... type 1 selected during therapy
@en
P2093
D D Richman
D Pauletti
J Sullivan
K Barringer
S A Spector
S Cheeseman
P2860
P304
P407
P577
1994-03-01T00:00:00Z